CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma

Wang, Guoqing; Zhang, Zongliang; Zhong, Kunhong; Wang, Zeng; Yang, Ning; Tang, Xin; Li, Hexian; Lu, Qizhong; Wu, Zhiguo; Yuan, Boyang; Zheng, Meijun; Cheng, Ping; Tong, Aiping; Zhou, Liangxue

doi:10.1016/j.ymthe.2022.08.021

Cited by 102 publications

(70 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…460,461 For instance, the lack of selectively and uniformly generated TAAs and the immunosuppressive tumor microenvironment are considered the biggest obstacles to successful CAR-Tcell therapy. [462][463][464] A combination of costimulatory factors and cytokines has been developed to improve CAR-T-cell activity and augment antitumor immunity. The expression of transgenic cytokines on CAR-T cells also enhances proliferative activity.…”

Section: Immune Checkpoint Blockade-based Immunotherapy For Osteosarcomamentioning

confidence: 99%

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

Tian

Cao

et al. 2023

Bone Res

View full text Add to dashboard Cite

Osteosarcoma, with poor survival after metastasis, is considered the most common primary bone cancer in adolescents. Notwithstanding the efforts of researchers, its five-year survival rate has only shown limited improvement, suggesting that existing therapeutic strategies are insufficient to meet clinical needs. Notably, immunotherapy has shown certain advantages over traditional tumor treatments in inhibiting metastasis. Therefore, managing the immune microenvironment in osteosarcoma can provide novel and valuable insight into the multifaceted mechanisms underlying the heterogeneity and progression of the disease. Additionally, given the advances in nanomedicine, there exist many advanced nanoplatforms for enhanced osteosarcoma immunotherapy with satisfactory physiochemical characteristics. Here, we review the classification, characteristics, and functions of the key components of the immune microenvironment in osteosarcoma. This review also emphasizes the application, progress, and prospects of osteosarcoma immunotherapy and discusses several nanomedicine-based options to enhance the efficiency of osteosarcoma treatment. Furthermore, we examine the disadvantages of standard treatments and present future perspectives for osteosarcoma immunotherapy.

show abstract

Section: Immune Checkpoint Blockade-based Immunotherapy For Osteosarcomamentioning

confidence: 99%

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

Tian

Cao

et al. 2023

Bone Res

View full text Add to dashboard Cite

show abstract

“…Likewise, Wang et al by using in vitro and in vivo assessments, advised CXCL11-armed oncolytic adenovirus as an improvement for immune-virotherapy as well as a promising adjuvant of CAR-T therapy for glioblastoma [ 160 ].…”

Section: Chemokine-targeting Therapies In Primary Brain Cancersmentioning

confidence: 99%

Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies

Ardizzone

Basilotta

Filippone

et al. 2023

Cells

View full text Add to dashboard Cite

Primary brain tumors are a leading cause of death worldwide and are characterized by extraordinary heterogeneity and high invasiveness. Current drug and radiotherapy therapies combined with surgical approaches tend to increase the five-year survival of affected patients, however, the overall mortality rate remains high, thus constituting a clinical challenge for which the discovery of new therapeutic strategies is needed. In this field, novel immunotherapy approaches, aimed at overcoming the complex immunosuppressive microenvironment, could represent a new method of treatment for central nervous system (CNS) tumors. Chemokines especially are a well-defined group of proteins that were so named due to their chemotactic properties of binding their receptors. Chemokines regulate the recruitment and/or tissue retention of immune cells as well as the mobilization of tumor cells that have undergone epithelial–mesenchymal transition, promoting tumor growth. On this basis, this review focuses on the function and involvement of chemokines and their receptors in primary brain tumors, specifically examining chemokine-targeting immunotherapies as one of the most promising strategies in neuro-oncology.

show abstract

“…One promising novel oncolytic adenovirus was engineered to be “armored” with the CD8+ T cell attracting chemokine CXCL1 and used in conjunction with CAR T-cell therapy [ 141 ]. The CXCL11 secretion was hypothesized to support CAR T-cell infiltration into the tumor and potentially increase infiltration of other lymphocytes expressing CXCR11.…”

Section: Car T-cell Advancements and Co-treatments To Overcome Immuno...mentioning

confidence: 99%

“…In a fully immunocompetent glioblastoma mouse model, the oAd-CXCL11 was combined with B7H3.CAR-T, and the combination was not only the most effective at reducing tumor progression and prolonging life of the mice but also increased infiltration of natural M1 macrophages, NK cells, and CD8+ T cells into the tumor, causing a shift in the TME profile. The combination of adenovirus-induced activation of the innate immune system and chemokine-induced lymphocyte infiltration proves a promising mechanism for altering the TME and increasing CAR T-cell infiltration and efficacy [ 141 ].…”

Section: Car T-cell Advancements and Co-treatments To Overcome Immuno...mentioning

confidence: 99%

Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors

Johnson

Townsend

O’Neill

2022

Cells

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T cells are an exciting advancement in cancer immunotherapy, with striking success in hematological cancers. However, in solid tumors, the unique immunosuppressive elements of the tumor microenvironment (TME) contribute to the failure of CAR T cells. This review discusses the cell populations, cytokine/chemokine profile, and metabolic immunosuppressive elements of the TME. This immunosuppressive TME causes CAR T-cell exhaustion and influences failure of CAR T cells to successfully infiltrate solid tumors. Recent advances in CAR T-cell development, which seek to overcome aspects of the TME immunosuppression, are also reviewed. Novel discoveries overcoming immunosuppressive limitations of the TME may lead to the success of CAR T cells in solid tumors.

show abstract

CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma

Cited by 102 publications

References 70 publications

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies

Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors

Contact Info

Product

Resources

About